Teucrium Sugar Fund Financials
This page shows Teucrium Sugar Fund (CANE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Asset-value swings, not operating scale, appear to drive results, while a cash-heavy balance sheet absorbs most of the volatility.
From FY2021 through FY2024, operating cash flow and net income moved in the same direction while selling/admin expense stayed near$300K , so reported gains and losses look tied mainly to asset exposures rather than to an expanding operating machine. Even interest expense reached$13.0M in FY2024, far above overhead, reinforcing that financial exposure matters more here than ordinary cost inflation.
The balance sheet stayed highly liquid, with cash still equal to
FY2025 shows a smaller accounting loss at
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Teucrium Sugar Fund's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Key Financial Metrics
Earnings & Revenue
Teucrium Sugar Fund reported -$26.5M in net income in fiscal year 2025. This represents an increase of 44.6% from the prior year.
Cash & Balance Sheet
Teucrium Sugar Fund held $205.3M in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Capital Allocation
CANE Income Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $2.0M | N/A | N/A | $11.1M | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $71K-9.2% | $78K+10.5% | $71K+28.0% | $55K+4.5% | $53K-57.3% | $124K+152.2% | $49K |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | $3.0M-13.6% | $3.5M-4.9% | $3.7M-19.0% | $4.6M-1.4% | $4.6M+10.5% | $4.2M-3.1% | $4.3M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$56K+99.5% | -$10.9M+53.5% | -$23.5M-366.1% | $8.8M+130.4% | -$29.0M-27.1% | -$22.8M+25.0% | -$30.5M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CANE Balance Sheet
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $241.7M-6.1% | $257.4M-4.0% | $268.0M-9.6% | $296.7M-9.0% | $326.0M-11.7% | $369.0M+1.2% | $364.7M-7.1% | $392.4M |
| Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $210.9M-9.6% | $233.3M+2.3% | $228.1M-10.1% | $253.7M-13.2% | $292.2M-9.4% | $322.5M+3.7% | $311.1M-5.8% | $330.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $17.0M+67.0% | $10.2M-62.2% | $27.0M+43.0% | $18.9M+65.3% | $11.4M-58.4% | $27.4M-39.7% | $45.4M+28.8% | $35.3M |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $224.6M-9.1% | $247.2M+2.5% | $241.0M-13.2% | $277.8M-11.7% | $314.5M-7.9% | $341.6M+7.0% | $319.3M-10.6% | $357.2M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CANE Cash Flow Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | -$1.6M-911.4% | $199K+100.8% | -$25.5M-555.4% | $5.6M+114.6% | -$38.3M-542.9% | -$6.0M+64.9% | -$17.0M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | $6.9M+126.6% | -$25.8M-97.5% | -$13.1M+63.6% | -$35.9M-172.1% | $49.8M+479.0% | -$13.1M+84.9% | -$87.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $25.3M-47.1% | $47.8M+77.9% | $26.9M-52.4% | $56.4M+46.9% | $38.4M-35.3% | $59.3M-46.5% | $110.9M |
CANE Financial Ratios
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | -2.8% | N/A | N/A | 79.3% | N/A | N/A | N/A |
| Return on Equity | N/A | -0.0%+4.5pp | -4.5%+3.9pp | -8.5%-11.3pp | 2.8%+11.3pp | -8.5%-1.3pp | -7.1%+1.4pp | -8.5% |
| Return on Assets | N/A | -0.0%+4.1pp | -4.1%+3.8pp | -7.9%-10.6pp | 2.7%+10.6pp | -7.9%-1.6pp | -6.3%+1.5pp | -7.8% |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 0.08+0.0 | 0.04-0.1 | 0.11+0.0 | 0.07+0.0 | 0.04-0.0 | 0.08-0.1 | 0.14+0.0 | 0.10 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
Is Teucrium Sugar Fund profitable?
No, Teucrium Sugar Fund (CANE) reported a net income of -$26.5M in fiscal year 2025.
How financially healthy is Teucrium Sugar Fund?
Teucrium Sugar Fund (CANE) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.